Argitalpenak (16) Manuel Ángel Barrera Gómez argitalpenak

filter_list Transplantation

2023

  1. Alternative forms of portal vein revascularization in liver transplant recipients with complex portal vein thrombosis

    Journal of Hepatology, Vol. 78, Núm. 4, pp. 794-804

2022

  1. Abdominal normothermic regional perfusion in controlled donation after circulatory determination of death liver transplantation: Outcomes and risk factors for graft loss

    American Journal of Transplantation, Vol. 22, Núm. 4, pp. 1169-1181

  2. DNA and RNA oxidative damage in hepatocellular carcinoma patients and mortality during the first year of liver transplantation

    World Journal of Hepatology, Vol. 14, Núm. 6, pp. 1182-1189

2020

  1. Breast implant during orthotopic liver transplant to avoid hepatic outflow obstruction

    Acta Chirurgica Belgica, Vol. 120, Núm. 2, pp. 146-147

2019

  1. A survey of Heads of Surgery and Residents on accessibility and employment in liver transplant teams in Spain

    Cirugia Espanola, Vol. 97, Núm. 10, pp. 560-567

  2. High serum caspase-3 levels in hepatocellular carcinoma prior to liver transplantation and high mortality risk during the first year after liver transplantation

    Expert Review of Molecular Diagnostics, Vol. 19, Núm. 7, pp. 635-640

  3. Low serum melatonin levels prior to liver transplantation in patients with hepatocellular carcinoma are associated with lower survival after liver transplantation

    International Journal of Molecular Sciences, Vol. 20, Núm. 7

  4. Normothermic regional perfusion vs. super-rapid recovery in controlled donation after circulatory death liver transplantation

    Journal of Hepatology, Vol. 70, Núm. 4, pp. 658-665

2018

  1. High serum soluble CD40L levels previously to liver transplantation in patients with hepatocellular carcinoma are associated with mortality at one year

    Journal of Critical Care, Vol. 43, pp. 316-320

  2. Patients with high serum substance P levels previously to liver transplantation for hepatocellular carcinoma have higher risk of one-year liver transplantation mortality

    Oncotarget, Vol. 9, Núm. 30, pp. 21552-21559

  3. Serum total antioxidant capacity prior to liver transplantation for hepatocellular carcinoma is associated with 1-year liver transplantation survival

    Journal of International Medical Research, Vol. 46, Núm. 7, pp. 2641-2649

2016

  1. Association between pre-transplant serum malondialdehyde levels and survival one year after liver transplantation for hepatocellular carcinoma

    International Journal of Molecular Sciences, Vol. 17, Núm. 4

  2. Prognostic value of serum Caspase-Cleaved Cytokeratin-18 levels before liver transplantation for one-year survival of patients with hepatocellular carcinoma

    International Journal of Molecular Sciences, Vol. 17, Núm. 9

  3. Selection of patients with hepatocellular carcinoma for liver transplantation: Past and future

    World Journal of Hepatology, Vol. 8, Núm. 1, pp. 58-68

2015

  1. Risk factors of hepatocellular carcinoma recurrence after liver transplantation: Accuracy of the alpha-fetoprotein model in a single-center experience

    Transplantation Proceedings

  2. V Reunión de Consenso de la Sociedad Española de Trasplante Hepático sobre receptores de riesgo elevado, escenarios actuales de inmunosupresión y manejo del hepatocarcinoma en espera de trasplante

    Cirugia Espanola, Vol. 93, Núm. 10, pp. 619-637